Evidence map›Paper›PMID 26055622›Full record

ArticleCardiovascular diabetology2015

Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.

Hao Luo, Xinquan Wang, Jialiang Wang, Caiyu Chen, Na Wang, Zaicheng Xu, Shuo Chen, Chunyu Zeng

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Activation of angiotensin II type 1 receptors increases DHypertension research : official journal of the Japanese Society of Hypertension · 2017
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hao LuoThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. lh060608@163.com.
Xinquan WangThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. 213474962@qq.com.
Jialiang WangThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. 575565291@qq.com.
Caiyu ChenThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. ccy19740920@163.com.
Na WangThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. 12826305@qq.com.
Zaicheng XuThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. 316296487@qq.com.
Shuo ChenThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. 919335951@qq.com.
Chunyu ZengThe Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, PR China. cyzeng01@163.com.
Daping Hospital · CNArmy Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBoth angiotensin II type 1 receptor (AT1R) and nuclear factor-kappa B (NF-κB) play significant roles in the pathogenesis of hypertension and type 2 diabetes. However, the role of NF-κB in perpetuating renal AT1 receptors dysfunction remains unclear. The aim of the present study to determine whether blockade of NF-κB, could reverse the exaggerated renal AT1R function, reduce inflammatory state and oxidative stress, lower blood pressure in Zucker diabetic fatty (ZDF) rats.

methodsPyrrolidine dithiocarbamate (PDTC), a NF-κB inhibitor (150 mg/kg in drinking water)or vehicle was administered orally to 12-weeks-old ZDF rats and their respective control lean Zucker (LZ) rats for 4 weeks. Blood pressure was measured weekly by tail-cuff method. AT1R functions were determined by measuring diuretic and natriuretic responses to AT1R antagonist (candesartan; 10 μg/kg/min iv). The mRNA and protein levels of NF-κB, oxidative stress maker and AT1R were determined using quantitative real-time PCR and Western blotting, respectively. The NF-κB-DNA binding activity in renal cortex was measured by Electrophoretic mobility shift assay (EMSA).

resultsAs compared with LZ rats, ZDF rats had higher blood pressure, impaired natriuresis and diuresis, accompanied with higher levels of oxidative stress and inflammation. Furthermore, AT1R expression was higher in renal cortex from ZDF rats; candesartan induced natriresis and diuresis, which was augmented in ZDF rats. Treatment with PDTC lowered blood pressure and improved diuretic and natriuretic effects in ZDF rats; meanwhile, the increased oxidative stress and inflammation were reduced; the increased AT1R expression and augmented candesartan-mediated natriuresis and diuresis were recoverd in ZDF rats. Our further study investigated the mechanisms of PDTC on AT1R receptor expression. It resulted that PDTC inhibited NF-κB translocation from cytosol to nucleus, inhibited binding of NF-κB with AT1R promoter, therefore, reduced AT1R expression and function.

conclusionsOur present study indicates blockade of NF-κB, via inhibition of binding of NF-κB with AT1R promoter, reduces renal AT1R expression and function, improves oxidative stress and inflammatory/anti-inflammatory balance, therefore, lowers blood pressure and recovers renal function in ZDF rats.

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsAntioxidantsBenzimidazolesBiphenyl CompoundsBlood PressureDiabetes Mellitus, Type 2DiuresisKidneyMaleNatriuresisNF-kappa BOxidative StressPromoter Regions, GeneticPyrrolidinesRatsAngiotensin II Type 1 Receptor BlockersAntioxidantsBenzimidazolesBiphenyl CompoundscandesartanNF-kappa Bpyrrolidine dithiocarbamic acidPyrrolidinesReceptor, Angiotensin, Type 1TetrazolesThiocarbamates

Identifiers

PMID26055622
PMCPMC4465496
OpenAlexW1593916133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.